New research has uncovered elevated rates of high blood sugar, or hyperglycemia, among patients with breast Cancer who are treated with the oral medication alpelisib. The results are published by� Wiley �online in� CANCER, a peer-reviewed journal of the American Cancer Society. Alpelisib targets the phosphoinositide 3-kinase (PI3K) protein that is involved in cell growth and when mutated can contribute to cancer. In 2019, the US Food and Drug Administration approved the use...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=311532